Allergan acquires Anterios to enhance neurotoxin delivery, bolsters Botox portfolio

Anterios' platform enables Botox and other neurotoxins to be delivered through the skin, rather than by injection. 

By Nicole Gray • Jan. 12, 2016

3 key biopharma manufacturing stories to keep an eye on in 2016

From compliance issues abroad to the developmental challenges of groundbreaking new therapies, here are some of the most important issues to watch in the world of biopharma manufacturing in the coming year.

By Sy Mukherjee • Jan. 7, 2016

India's Cadila to snap up plant, animal health products from Pfizer spinoff Zoetis

Cadila will pay $29 million in a deal expected to close sometime in the first quarter. 

By Ned Pagliarulo • Jan. 7, 2016

J&J may sell off its Noramco manufacturing unit in $800 million deal

That's according to sources familiar with the situation, Reuters reports. The unit produces active ingredients for painkillers.

By Sy Mukherjee • Jan. 7, 2016

In efficiency bid, Novartis selling Alcon unit to Recipharm in $20M deal

Recipharm will expand its presence in France—one of its seven key operational regions. 

By Nicole Gray • Jan. 7, 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.

By Nicole Gray • Jan. 4, 2016

11 biopharma execs & experts look back on 2015: A record year for record-breaking

We spoke with bigwigs from Sanofi, the Biosimilars Council, Novocure, Accenture, Bain, amfAR, Boehringer Ingelheim, and more on what they considered the most significant events that drove biopharma this past year.

By Nicole Gray • Dec. 22, 2015

With eye on the future, AstraZeneca to beef up manufacturing, R&D presence in China

Investing directly in manufacturing and R&D capabilities in the country is seen as critical for future drug approvals in the market. 

By Nicole Gray • Dec. 17, 2015

Mylan to Strides: Help us cover the tab for your noncompliant plants

There were signs of problems at several Bangalore-based facilities before Mylan acquired Strides Arcolabs in late 2014. 

By Nicole Gray • Dec. 16, 2015

New study: Too many factories, too few inspectors for India's pharma industry

A review by Assocham/RNCOS found that there are roughly 1,500 qualified inspectors for 10,000 Indian manufacturing facilities. 

By Nicole Gray • Dec. 11, 2015

How China is getting serious about developing quality drugs right at home

As Chinese biopharma companies experience substantial growth, China hopes to further foster a domestic drug market.

By Nicole Gray • Dec. 1, 2015

CAR-T companies scale up production with eye towards lowering costs

Kite Pharma has successfully cut the production time and cost of developing re-engineered T-cells for cancer treatment.

By Nicole Gray • Nov. 19, 2015

Roche to slash up to 1,200 jobs, shutter 4 plants in US and EU in major restructuring

The company will be charged $1.6 billion through 2021 in order to carry out the plant closures.

By Nicole Gray • Nov. 13, 2015

China FDA cracks down on pharmas in quality control effort

The China Food and Drug Administration (CFDA) has rejected 11 drug applications from eight companies in the midst of a major health reform initiative. 

By Nicole Gray • Nov. 13, 2015

AstraZeneca to generics makers: Back off our 'purple pill'

AZ recently lost patent protection on its flagship Nexium (esomeprazole) in the U.S., opening the door to generic competition—and potential trademark infringement. 

By Nicole Gray • Nov. 3, 2015

FDA alleges major violations, use of old ingredients at Chinese Pfizer plant

During an inspection in April, FDA inspectors turned up quality failures and use of expired materials at a plant in Dalian. The agency also says the plant tried to obfuscate its shortcomings.

By Nicole Gray • Nov. 2, 2015

The next challenge for CAR-T: Large-scale production

Experts predict that the first CAR-T therapy will be available in 2016, but production costs wil range from $50,000 to $100,000 per patient. 

By Nicole Gray • Nov. 2, 2015

Drug shortages & patent expiration: Authorized generics as more than a lifecycle strategy

We spoke with Dr. Cary Yonce, Vice President of General Therapeutics and Life Cycle Management at Sanofi, about the patient demand for generic Arava and the company's response to that demand 10 years after patent expiry.

By Nicole Gray • Oct. 27, 2015

Chinese firm plans large-scale production of Ebola vaccine

Tianjin CanSino Biotechnology, which is privately held, is investing $315 million in an Ebola vaccine-maufacturing facility. 

By Nicole Gray • Oct. 15, 2015

Glaxo shutting down French research lab, laying off 70 employees

Work that was being done at the plants will shift to global hubs.

By Nicole Gray • Sept. 28, 2015

Study: Cancer drugs in US cost up to 6,000% of production cost

Patients in the U.S. pay more than twice as much for tyrosine kinase inhibitors (TKIs), used to treat cancer, than their European counterparts.

By Nicole Gray • Sept. 23, 2015

10th Indian pharma plant this year makes FDA's do-not-import list

Once again, the problem at hand is production quality. 

By Nicole Gray • Sept. 15, 2015

Georgia opens $14M bioscience training center next to Baxalta plant

The new Bioscience Training Center is across the street from Baxalta's $1 billion biomanufacturing plant in Covington, GA. 

By Nicole Gray • Sept. 11, 2015

Russia's Putin reiterates commitment to 90% domestic drug-making by 2020

Pharma 2020 was launched in 2011 by Vladimir Putin in order to intensify domestic investment in the national pharmaceutical industry. 

By Nicole Gray • Sept. 10, 2015

Moody's upgrades financial outlook for biopharma industry

The ratings firm shifted the sector from "stable" to "positive" based on success of new products.

By Nicole Gray • Sept. 4, 2015